Evidence map›Paper›PMID 37173551›Full record

ArticleThe AAPS journal2023

Amgen v. Sanofi: Critical Impact on the Value of Innovative Science in Antibody Discovery.

Joseph P Balthasar

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The AAPS journal, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Joseph P BalthasarDepartment of Pharmaceutical Sciences, School of Pharmacy and Pharmaceutical Sciences, University at Buffalo, 452 Pharmacy Building, Buffalo, New York, 14214, USA. jb@buffalo.edu.

Funding

Enhancement of ADC selectivity by inverse targeting: Mechanistic studies and optimizationR01CA256928 · NCI · STATE UNIVERSITY OF NEW YORK AT BUFFALO · PI BALTHASAR, JOSEPH P · 2021 to 2025
$1.8M
Pharmacokinetic strategies to increase monoclonal antibody uptake, distribution, and efficacy for treatment of solid tumorsR01CA246785 · NCI · STATE UNIVERSITY OF NEW YORK AT BUFFALO · PI BALTHASAR, JOSEPH P, SHAH, DHAVAL K · 2020 to 2024
$1.8M
Pharmacokinetic / Pharmacodynamic Optimization of ADC Therapy for Acute Myeloid LeukemiaR01CA275967 · NCI · STATE UNIVERSITY OF NEW YORK AT BUFFALO · PI Joseph P Balthasar, Dhaval K Shah · 2023 to 2026
$1.7M
Lead Optimization and Evaluation of Anti-SN38 Payload Binding Selectivity EnhancersR43CA261343 · NCI · ABCEUTICS INC. · PI WIENKERS, LARRY C · 2021 to 2021
$168k
NCI NIH HHS R01 CA246785NCI NIH HHS R01 CA256928NCI NIH HHS R01 CA275967NCI NIH HHS R43 CA261343
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

AntibodyDiscoveryMonoclonal AntibodyPatent

Identifiers

PMID37173551
PMCPMC10809895

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.